ACCENDRA HEALTH INC (ACH)
Sector: Health Care
2026 Annual Meeting Analysis
ACCENDRA HEALTH INC · Meeting: May 14, 2026
Directors FOR
0
Directors AGAINST
6
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Mr. Beck has served since 2019, giving him full overlap with ACH's severe 3-year stock decline of -80.7%, which trails the company's own peer group by 88.7 percentage points — far exceeding the 20-point trigger — and the 5-year record is even worse at -100.2pp below peers, so the longer-term mitigant does not apply.
Ms. Bingham has served since 2020, covering virtually the entire 3-year underperformance period in which ACH fell -80.7% while peer companies gained a median of 8.0%, a gap of 88.7 percentage points; the 5-year record shows no improvement, so no mitigant applies.
Mr. Gardner-Smith joined in 2022, placing him beyond the 24-month new-director exemption, and his tenure covers the core of the 3-year underperformance period; ACH's stock loss of -80.7% versus a peer median gain of 8.0% represents an 88.7pp gap, and the 5-year comparison at -100.2pp also triggers, so no mitigant is available.
Mr. Klemash has served since 2021, giving him substantial overlap with the 3-year period in which ACH lost -80.7% while peers gained 8.0% on median — an 88.7pp gap that far exceeds the 20pp trigger — and the 5-year comparison confirms the underperformance is sustained, not a recent blip.
Ms. Kline joined in 2022 and is beyond the new-director exemption; her tenure coincides with the bulk of ACH's -80.7% stock decline versus a peer median gain of 8.0%, a gap of 88.7pp, and the 5-year comparison at -100.2pp below peers also triggers, eliminating any longer-track-record mitigant.
As both CEO and director since 2019, Mr. Pesicka bears the most direct accountability for ACH's catastrophic stock performance — a -80.7% three-year decline versus a peer median gain of 8.0% (a gap of 88.7pp) — and the 5-year picture is worse at -100.2pp below peers, so no mitigant applies; this AGAINST vote on his director seat is independent of the separate Say on Pay analysis.
For Analysis
All six director nominees trigger the TSR underperformance policy. ACH's 3-year stock return of -80.7% trails the company's own disclosed compensation peer group median of +8.0% by 88.7 percentage points, far exceeding the 20pp threshold that applies when absolute returns are negative. The 5-year comparison (-100.2pp below peers) confirms that underperformance is sustained, eliminating the longer-track-record mitigant for all directors. No director benefits from the new-director (under 24 months) exemption. The policy requires an AGAINST vote on each director individually.
Say on Pay
✗ AGAINSTCEO
Edward A. Pesicka
Total Comp
$11,157,809
Prior Support
95%%
ACH's stock has lost 80.7% over three years while peers gained a median of 8.0%, yet the CEO received total compensation of $11.16 million in 2025 — a level calibrated to a far larger company than the current $201 million market cap. The pay-for-performance alignment check fails: the company missed every single one of its 2025 financial targets at 0% achievement (EBITDA, revenue, and net debt reduction all came in below threshold), yet the CEO was still awarded $345,000 in bonus pay plus $9.56 million in equity grants. While the company's rationale for a modest 20% bonus payout — recognizing the CEO's role in the P&HS divestiture — has some merit, the overall compensation package is not aligned with the experience of shareholders who have seen their investment lose roughly 93% of its value over five years, making a FOR vote inappropriate.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
N/A
Audit Fees
$5,402,360
Non-Audit Fees
$758,628
Non-audit fees (audit-related fees of $555,000 plus tax fees of $49,728 plus other fees of $153,900, totaling approximately $758,628) represent roughly 14% of audit fees of $5,402,360 — comfortably below the 50% threshold that would raise independence concerns. KPMG is a Big 4 firm that is fully appropriate for a company of ACH's size and complexity. Auditor tenure is not disclosed in the proxy, so the tenure trigger cannot fire; this is noted as a minor negative but does not change the vote.
Overall Assessment
This ballot presents significant governance concerns at Accendra Health: the stock has lost over 80% in three years while trailing its own peer group by nearly 90 percentage points, triggering AGAINST votes on all six director nominees and the Say on Pay proposal. The auditor ratification passes cleanly on fee ratios, and the equity plan approval falls outside current policy coverage.
Compensation Peer Group
14 companies disclosed in 2026 proxy filing